Evra 6 mg Transdermal Patch
PDF Leaflet Revision Date: 23 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of pregnancy.
Dosage (summary)
One patch applied weekly for 3 weeks, followed by a patch-free week.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; may affect lactation and cause adverse effects in breastfed infants.
Key Drug Interactions
- CYP3A4 inducers
- CYP3A4 inhibitors
- St. John's Wort
Contraindications
- Hypersensitivity
- Thromboembolic disorders
- Migraine
- Uncontrolled hypertension
- Known or suspected pregnancy
Common side effects
- Headache
- Nausea
- Breast symptoms
- Application site disorder
Counselling Points
- Apply to clean, dry skin
- Check patch daily for adhesion
- Use additional contraception if patch is detached for >24 hours
Serious warnings
- Increased risk of thromboembolic events
- Smoking increases cardiovascular risk
- Monitor blood pressure
Important Disclaimer
The Evra 6 mg Transdermal Patch professional information leaflet below is the property of Acino Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
